Per Peterson, M.D., Ph.D., Joins Board of Directors of Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) today announced that Per Peterson, M.D., Ph.D. has been appointed to its board of directors, effective March 1, 2007. Dr. Peterson recently retired as Chairman, Research & Development, at Johnson & Johnson. As Chairman, he had responsibility for the Corporate Office of Science and Technology, the Enterprise-wide R&D Council, and Johnson & Johnson's cell therapy research activities. Dr. Peterson was also a member of the Executive Committee of Johnson & Johnson.

"We are very pleased to be adding someone of Dr. Peterson's reputation and experience to our board," said Greg Lucier, Invitrogen's Chairman and Chief Executive Officer. "As a leader in the life sciences, we are focused on creating technologies that accelerate biological understanding. In his role as director, Dr. Peterson will provide invaluable insight, advice and guidance to ensure Invitrogen remains on the cutting edge of innovation that makes a difference to researchers."

Dr. Peterson joined Johnson & Johnson in 1994 as Vice President, Drug Discovery, of the R.W. Johnson Pharmaceutical Research Institute. He was named Group Vice President of the Pharmaceutical Research Institute in April 1998 and its President in November 1998. In 2000, Dr. Peterson was named Chairman, Research & Development, Pharmaceuticals Group. Dr. Peterson became a Member of the Executive Committee in 2001.

Prior to joining Johnson & Johnson, Dr. Peterson spent eight years at Scripps Research Institute in La Jolla, CA, where he headed the Division of Molecular Immunogenetics before being appointed Chairman of the Department of Immunology in 1987. He had earlier served as Director of the Wallenberg Laboratory, as well as professor of cell biology at the University of Uppsala, Sweden.

Born in Kalmar, Sweden, Dr. Peterson received his B.M. in Medicine and his Ph.D. in Medicinal Biochemistry from the University of Uppsala, Sweden.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 5,000 scientists and other professionals and had revenues of more than $1.26 billion in 2006. For more information, visit www.invitrogen.com